The crowded part of the gene-editing estate is the part that cuts DNA. The white space, in 2020 at least, sat in the modalities that change how a gene behaves without touching its sequence - and US10612044B2, "DNA methylation editing kit and DNA methylation editing method," issued April 7, 2020 to National University Corporation Gunma University, stakes a claim there.
Epigenome editing alters chemical marks - here, DNA methylation - that control whether a gene is read, leaving the underlying sequence intact. That is a categorically different invention from a Cas nuclease that creates a double-strand break, and it draws on a different prior-art pool. A freedom-to-operate analysis for a cutting-based program may clear this patent entirely, and vice versa.
The CPC profile is the tell. Alongside C12N 15/907 (editing machinery) the grant carries methyltransferase and antibody-related tags (C12N 9/10, C07K 16/18, C07K 16/44). That cross-class signature - editing tooling plus enzyme and antibody chemistry - is unusual for the cutting estate and marks the patent as occupying a distinct technical lane.
For a portfolio strategist, the lesson is that 'gene editing' is not a single freedom-to-operate question. A program built on transcriptional or epigenetic control navigates a sparser claim landscape than one built on nucleases, and a grant like this is where that sparser landscape starts to fill in. Mapping the white space means tracking the non-cutting modalities separately.
It also flags where later filing velocity would concentrate. As the field matured, epigenome and transcriptional editing attracted their own wave of applications; the 2020 methylation grants are the early boundary stones of that neighborhood, useful as anchors when assessing whether a newer program has genuine room to operate.